What is the primary use of Fresh Frozen Plasma (FFP)?

Fresh Frozen Plasma (FFP) is primarily utilized to supply coagulation factors for patients, particularly in situations where there is a need for rapid correction of coagulopathy or when patients have significant bleeding due to deficiencies in clotting factors. FFP is rich in clotting factors, including fibrinogen, prothrombin, and various others, making it essential in managing conditions such as disseminated intravascular coagulation (DIC), liver disease, or massive transfusion protocols where coagulation factors may be depleted.

The use of FFP aligns with guidelines indicating that it should be administered when there is a clear indication of bleeding and laboratory evidence of coagulopathy, such as prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT). This provides a vascular supply of factors that are necessary to restore hemostatic balance.

While it is true that FFP can provide immediate transfusion therapy, this is not its primary intent; rather, it is a means to deliver those crucial coagulation factors directly. Anemia treatment and immune response enhancement are more related to red blood cell transfusions and other specific therapies, rather than the direct application of FFP. Thus, the focus on coagulation factor supply